Cue Biopharma Licenses Immuno-STAT® Oncology Technology to ImmunoScape

Reuters
2025.11.13 18:11
portai
I'm PortAI, I can summarize articles.

Cue Biopharma Inc. has entered an exclusive in-licensing agreement with ImmunoScape Pte. Ltd. ImmunoScape will gain exclusive access to Cue Biopharma’s Immuno-STAT® molecules for oncology development. The collaboration aims to advance TCR-based cancer immunotherapies, especially for solid tumors.

Cue Biopharma Inc. has announced an exclusive in-licensing agreement with Singapore-based ImmunoScape Pte. Ltd. Under the terms of the deal, ImmunoScape will gain exclusive access to Cue Biopharma’s clinical-stage Immuno-STAT® molecules for development in oncology. The collaboration aims to advance next-generation TCR-based cancer immunotherapies, particularly for solid tumor cancers. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cue Biopharma Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251113268855) on November 13, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)

Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer